Literature DB >> 9038325

A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines.

P E Duffy1, D C Kaslow.   

Abstract

Antibodies to Pfs28 block Plasmodium falciparum transmission and when combined with antibodies to Pfs25 provide synergy in blocking transmission. Pfs28 and Pfs25 are immunogenic, have limited antigenic diversity, and are structurally similar and genetically linked on chromosome 10. Pfs28 may prove a useful addition to Pfs25 in an effective transmission-blocking vaccine.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9038325      PMCID： PMC175097     

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  12 in total

1.  Comparison of the primary structure of the 25 kDa ookinete surface antigens of Plasmodium falciparum and Plasmodium gallinaceum reveal six conserved regions.

Authors:  D C Kaslow; C Syin; T F McCutchan; L H Miller
Journal:  Mol Biochem Parasitol       Date:  1989-03-15       Impact factor: 1.759

2.  Plasmodium falciparum appears to have arisen as a result of lateral transfer between avian and human hosts.

Authors:  A P Waters; D G Higgins; T F McCutchan
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

3.  Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum.

Authors:  D C Kaslow; I C Bathurst; T Lensen; T Ponnudurai; P J Barr; D B Keister
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

4.  Structure and expression of a post-transcriptionally regulated malaria gene encoding a surface protein from the sexual stages of Plasmodium berghei.

Authors:  M G Paton; G C Barker; H Matsuoka; J Ramesar; C J Janse; A P Waters; R E Sinden
Journal:  Mol Biochem Parasitol       Date:  1993-06       Impact factor: 1.759

5.  Antigenic diversity and the transmission dynamics of Plasmodium falciparum.

Authors:  S Gupta; K Trenholme; R M Anderson; K P Day
Journal:  Science       Date:  1994-02-18       Impact factor: 47.728

6.  Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose.

Authors:  D C Kaslow; J Shiloach
Journal:  Biotechnology (N Y)       Date:  1994-05

7.  A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains.

Authors:  D C Kaslow; I A Quakyi; C Syin; M G Raum; D B Keister; J E Coligan; T F McCutchan; L H Miller
Journal:  Nature       Date:  1988-05-05       Impact factor: 49.962

8.  Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito.

Authors:  A N Vermeulen; T Ponnudurai; P J Beckers; J P Verhave; M A Smits; J H Meuwissen
Journal:  J Exp Med       Date:  1985-11-01       Impact factor: 14.307

9.  Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals.

Authors:  P J Barr; K M Green; H L Gibson; I C Bathurst; I A Quakyi; D C Kaslow
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

10.  Pgs28 belongs to a family of epidermal growth factor-like antigens that are targets of malaria transmission-blocking antibodies.

Authors:  P E Duffy; P Pimenta; D C Kaslow
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307
View more
  60 in total

1.  Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies.

Authors:  C A Lobo; R Dhar; N Kumar
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions.

Authors:  A M Tomas; G Margos; G Dimopoulos; L H van Lin; T F de Koning-Ward; R Sinha; P Lupetti; A L Beetsma; M C Rodriguez; M Karras; A Hager; J Mendoza; G A Butcher; F Kafatos; C J Janse; A P Waters; R E Sinden
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

3.  Blocking effect of a monoclonal antibody against recombinant Pvs25 on sporozoite development in Anopheles sinensis.

Authors:  Sung-Ung Moon; Hyung-Hwan Kim; Tong-Soo Kim; Kyung-Mi Choi; Chang-Mi Oh; Yong-Joo Ahn; Seo-Kyoung Hwang; Youngjoo Sohn; E-Hyun Shin; Hyuck Kim; Hyeong-Woo Lee
Journal:  Clin Vaccine Immunol       Date:  2010-06-16

4.  In vitro generation of Plasmodium falciparum ookinetes.

Authors:  Viengngeun Bounkeua; Fengwu Li; Joseph M Vinetz
Journal:  Am J Trop Med Hyg       Date:  2010-12       Impact factor: 2.345

5.  Malaria parasites form filamentous cell-to-cell connections during reproduction in the mosquito midgut.

Authors:  Ingrid Rupp; Ludmilla Sologub; Kim C Williamson; Matthias Scheuermayer; Luc Reininger; Christian Doerig; Saliha Eksi; Davy U Kombila; Matthias Frank; Gabriele Pradel
Journal:  Cell Res       Date:  2010-12-21       Impact factor: 25.617

Review 6.  Plasmodium p25 and p28 surface proteins: potential transmission-blocking vaccines.

Authors:  Ajay K Saxena; Yimin Wu; David N Garboczi
Journal:  Eukaryot Cell       Date:  2007-06-08

7.  Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.

Authors:  Cevayir Coban; Ken J Ishii; Anthony W Stowers; David B Keister; Dennis M Klinman; Nirbhay Kumar
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.

Authors:  T Tsuboi; D C Kaslow; M M Gozar; M Tachibana; Y M Cao; M Torii
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

9.  Enhanced antibody responses to Plasmodium falciparum Pfs28 induced in mice by conjugation to ExoProtein A of Pseudomonas aeruginosa with an improved procedure.

Authors:  Feng Qian; Joan A Aebig; Karine Reiter; Emma Barnafo; Yanling Zhang; Richard L Shimp; Kelly M Rausch; David S Jones; Daming Zhu; Lynn Lambert; Gregory E D Mullen; David L Narum; Louis H Miller; Yimin Wu
Journal:  Microbes Infect       Date:  2008-12-27       Impact factor: 2.700

10.  Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.

Authors:  Yue Qiu; Yan Zhao; Fei Liu; Bo Ye; Zhenjun Zhao; Sataporn Thongpoon; Wanlapa Roobsoong; Jetsumon Sattabongkot; Liwang Cui; Qi Fan; Yaming Cao
Journal:  Vaccine       Date:  2020-02-21       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.